GHRH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Geologists consider her to be the "first woman geologist in this country (America)". 1893: American botanist Elizabeth Gertrude Britton became a charter member of the Botanical Society of America. 1894: American astronomer Margaretta Palmer became the first woman to earn a doctorate in astronomy. 1895: English physiologist Marion Bidder became the first woman to speak and present her own paper at a meeting of the Royal Society. 1896: Florence Bascom became the first woman to work for the United States Geological Survey. 1896: English mycologist and lichenologist Annie Lorrain Smith became a founding member of the British Mycological Society. She later served as president twice. 1896: Russian ophthalmologist Rosa Kerschbaumer-Putjata graduated from the University of Bern. She became the first female doctor permitted to practice in Austria due to a special permit granted by Emperor Franz Joseph I of Austria. She campaigned for women's right to study medicine in Austria. 1897: American cytologists and zoologists Katharine Foot and Ella Church Strobell started working as research partners. Together, they pioneered the practice of photographing microscopic research samples and invented a new technique for creating thin material samples in colder temperatures. 1897: American physicist Isabelle Stone became the first woman to receive a PhD in physics in the United States. She wrote her dissertation "On the Electrical Resistance of Thin Films" at the University of Chicago.
==== Angiogenesis and obesity ==== Studies have disagreed about the effects of FFAR2 on adipogenesis (i.e., formation of fat cells and fat tissue from precursor cells) as well as on the development of obesity. The inconsistencies reported by different research groups need to be resolved through further research in order to develop a clear picture of the actions that FFAR2 has on adipogenesis and obesity.
Coca tea, also called mate de coca, is a herbal tea (infusion) made using the raw or dried leaves of the cocaine-containing coca plant, which is native to South America. It is made either by submerging the coca leaf or steeping a tea bag in hot water. The tea is most commonly consumed in the Andes mountain range, particularly Argentina, Bolivia, Colombia, Ecuador and especially in Peru, where it is consumed all around the country. It is greenish yellow in color and has a mild bitter flavor similar to green tea with a more organic sweetness. There is no evidence that the use of coca tea leads to dependence or addiction, potentially due to the low concentrations of cocaine present. Though also known as mate, mate de coca is made from a different plant than the yerba mate drink in southeastern South America.
Flotufolastat (18F), sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The active ingredient is flotufolastat (18F). Flotufolastat (18F) was approved for medical use in the United States in May 2023.
hemizygous In a diploid organism, having just one allele at a given genetic locus (where there would ordinarily be two). Hemizygosity may be observed when only one copy of a chromosome is present in a normally diploid cell or organism, or when a segment of a chromosome containing one copy of an allele is deleted, or when a gene is located on a sex chromosome in the heterogametic sex (in which the sex chromosomes do not exist in matching pairs); for example, in human males with normal chromosomes, almost all X-linked genes are said to be hemizygous because there is only one X chromosome and few of the same genes exist on the Y chromosome.
Sources: en.wikipedia.org
Cl2 + H2O ⇌ HClO + HCl Cl2 + 4 OH− ⇌ 2 ClO− + 2 H2O + 2 e− Cl2 + 2 e− ⇌ 2 Cl− When acids are added to aqueous salts of hypochlorous acid (such as sodium hypochlorite in commercial bleach solution), the resultant reaction is driven to the left, and chlorine gas is formed. Thus, the formation of stable hypochlorite bleaches is facilitated by dissolving chlorine gas into basic water solutions, such as sodium hydroxide. The acid can also be prepared by dissolving dichlorine monoxide in water; under standard aqueous conditions, anhydrous hypochlorous acid is currently impossible to prepare due to the readily reversible equilibrium between it and its anhydride:
In fluid dynamics, the Hagen–Poiseuille equation, also known as the Hagen–Poiseuille law, Poiseuille law or Poiseuille equation, is a physical law that gives the pressure drop in an incompressible and Newtonian fluid in laminar flow flowing through a long cylindrical pipe of constant cross section. It can be successfully applied to air flow in the airways of the lungs, or the flow through a drinking straw or through a hypodermic needle. It was experimentally derived independently by Jean Léonard Marie Poiseuille in 1838 and Gotthilf Heinrich Ludwig Hagen, and published by Hagen in 1839 and then by Poiseuille in 1840–41 and 1846. The theoretical justification of the Poiseuille law was given by George Stokes in 1845. The assumptions of the equation are that the fluid is incompressible and Newtonian; the flow is laminar through a pipe of constant circular cross-section that is substantially longer than its diameter; and there is no acceleration of fluid in the pipe. For velocities and pipe diameters above a threshold, actual fluid flow is not laminar but turbulent, leading to larger pressure drops than calculated by the Hagen–Poiseuille equation. Poiseuille's equation describes the pressure drop due to the viscosity of the fluid; other types of pressure drops may still occur in a fluid (see a demonstration here).
== History == In 1916, Bennett M. Allen and Philip E. Smith found that the pituitary contained a thyrotropic substance. The first standardised purification protocol for this thyrotropic hormone was described by Charles George Lambie and Victor Trikojus, working at the University of Sydney in 1937.
The Beltrán-Leyva Cartel was founded by the four Beltrán Leyva brothers: Marcos Arturo, Carlos, Alfredo and Héctor. In 2004 and 2005, cartel leader Arturo Beltrán Leyva led groups of enforcers to compete for trafficking routes in northeastern Mexico against the Sinaloa Cartel. The Beltrán-Leyva Cartel infiltrated Mexico's political, judicial, and police institutions, including the Interpol in Mexico, to feed classified information about anti-drug operations against its rivals. Following the 2009 killing of Arturo Beltrán Leyva, the cartel entered into an internal power struggle between Arturo's brother, Héctor Beltrán Leyva, and his top enforcer Edgar Valdez Villarreal. Meanwhile, the cartel continued to dissolve with factions such as the South Pacific Cartel, La Mano Con Ojos, Independent Cartel of Acapulco, and La Barredora forming and the latter two cartels starting yet another intra-Beltrán Leyva Cartel conflict. The Mexican Federal Police considers the cartel to have been disbanded, and their last leader, Héctor Beltrán Leyva, was captured in October 2014.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.